Evaluation of a short-term topical interferon α-2b treatment for histologically proven melanoma and primary acquired melanosis with atypia-Reference-Cited by-同舟云学术

Evaluation of a short-term topical interferon α-2b treatment for histologically proven melanoma and primary acquired melanosis with atypia

Published:2015-12-04 Issue:1 Volume:35 Page:29-34
ISSN:0167-6830
Container-title:Orbit
language:en
Short-container-title:Orbit

Author:

Garip Aylin¹,Schaumberger Markus M.¹,Wolf Armin¹,Herold Tina R.¹,Miller Christina V.¹,Klingenstein Annemarie¹,Schebitz-Walter Kirsten²,Hintschich Christoph R.²

Affiliation:

1. Department of Ophthalmology, Ludwig-Maximilians-University, Munich, Germany

2. Section of Oculoplastic and Reconstructive Surgery, Department of Ophthalmology, Ludwig-Maximilians-University, Munich, Germany

Publisher

Informa UK Limited

Subject

Ophthalmology

Link

https://www.tandfonline.com/doi/pdf/10.3109/01676830.2015.1093509

Reference23 articles.

1. Clinical survey of 1643 melanocytic and nonmelanocytic conjunctival tumors

2. Conjunctival Melanoma

3. Primary Acquired Melanosis of the Conjunctiva: Risks for Progression to Melanoma in 311 Eyes

4. Primary acquired melanosis of the conjunctiva

5. Malignant Melanoma of the Conjunctiva

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Toxicity and efficacy of type I interferons on the ocular surface: in vitro, animal, and clinical studies;The Ocular Surface;2024-10

2. Current Practice in the Treatment of Epithelial and Melanocytic Tumours with Interferon-α2b: A Survey of Tertiary Eye Centres in Germany;Klinische Monatsblätter für Augenheilkunde;2023-02-06

3. Real-life data of adjuvant IFN-α2b and MMC in conjunctival melanocytic lesions;Graefe's Archive for Clinical and Experimental Ophthalmology;2022-10-18

4. Use of interferon alpha 2b to manage conjunctival primary acquired melanosis and conjunctival melanoma;Survey of Ophthalmology;2022-09

5. Adjunctive Treatment with Interferon Alpha 2b in Conjunctival Melanoma;Ocular Oncology and Pathology;2022